Overview
Indications
Symptomatic Trichomoniasis. T. vaginalis Metronidazole tablets are indicated for the treatment ofinfection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. T. vaginalis Metronidazole tablets are indicated in the treatment of asymptomaticinfection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that pre
Boxed Warning
FDA Black Box Warning
WARNING PRECAUTIONS INDICATIONS AND USAGE Metronidazole has been shown to be carcinogenic in mice and rats (see). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in thesection below.
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
150 trials linked to this intervention
Recent Trials
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
Leukocyte Depletion of Autologous Whole Blood
Study of the Use of Coated Venous Catheters in the Critically Ill Child
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Metronidazole (substance)
- SNOMED CT
- 372602008
- UMLS CUI
- C0025872
- RxNorm CUI
- 6922
- Labeler
- BluePoint Laboratories
Clinical Data
This intervention maps to 18 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.